Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15800 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Hideaki Hashimoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Glomerular Filtration Rate, Diabetes Mellitus, Type 2, Diabetic Nephropathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan, Bayer Yakuhin Co., Ltd, Daiwa Securities Foundation.
Abstract (Originalsprache)
Aim
To evaluate the renal prognosis of dipeptidyl peptidase‐4 inhibitor (DPP‐4i) users and non‐users using real‐world Asian data.
Methods
Using databases from DeSC Healthcare, Inc., patients aged 30 years or older who used antidiabetic drugs from 2014 to 2021 were identified. Propensity score matching analyses were used to compare renal prognosis between DPP‐4i users and non‐users. The primary outcomes were estimated glomerular filtration rate (eGFR) decline and end‐stage kidney disease (ESKD) development in the eGFR of 45 mL/min/1.73m 2 or higher and eGFR of less than 45 mL/min/1.73m 2 groups, respectively.
Results
In total, 65 375 and 9866 patients were identified in the eGFR of 45 mL/min/1.73m 2 or higher and eGFR of less than 45 mL/min/1.73m 2 groups, respectively. In the eGFR of 45 mL/min/1.73m 2 or higher group, propensity score matching created 16 002 pairs. A significant difference was observed in the primary outcome of eGFR decline between DPP‐4i users and non‐users at 2 years (−2.31 vs. −2.56 mL/min/1.73m 2 : difference, 0.25 mL/min/1.73m 2 ; 95% confidence interval [CI], 0.06‐0.44) and 3 years (−2.75 vs. −3.41 mL/min/1.73m 2 : difference, 0.66 mL/min/1.73m 2 ; 95% CI, 0.39‐0.93). In the eGFR less than 45 mL/min/1.73m 2 group, propensity score matching created 2086 pairs. After a mean of 2.2 years of observation, ESKD development was 1.15% and 2.30% in users and non‐users, respectively, and Kaplan–Meier analysis revealed a significant difference (log rank P = .005).
Conclusions
This retrospective real‐world study revealed that patients using DPP‐4is had a better renal prognosis than those not using DPP‐4is.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
- Division of Public Health, Hygiene and Epidemiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
- Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
- Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
- Department of Nephrology, Self-Defense Forces Sendai Hospital, Sendai, Japan.
- Division of Aging and Geriatric Dentistry, Department of Rehabilitation Dentistry, Tohoku University Graduate School of Dentistry, Sendai, Japan.
ORCID-Profile: Hideaki Hashimoto, Hirohito Metoki
Förderung
- Ministry of Education, Culture, Sports, Science and Technology, Japan
- Bayer Yakuhin Co., Ltd
- Daiwa Securities Foundation
- Medical Research Encouragement Prize of the Japan Medical Association
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Hashimoto, H., Satoh, M., Nakayama, S., Toyama, M., Murakami, T., Obara, T., Nakaya, N., Mori, T., Hozawa, A., & Metoki, H. (2024). Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15800
Vancouver
Hashimoto H, Satoh M, Nakayama S, Toyama M, Murakami T, Obara T, et al. Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15800
BibTeX
@article{Hashimoto2024,
author = {Hashimoto, Hideaki and Satoh, Michihiro and Nakayama, Shingo and Toyama, Maya and Murakami, Takahisa and Obara, Taku and Nakaya, Naoki and Mori, Takefumi and Hozawa, Atushi and Metoki, Hirohito},
title = {Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15800}
}
EUVIMED